Fulcrum Therapeutics (FULC)
NASDAQ:FULC
Want to see FULC full AI Analyst Report?
Total Valuation
Fulcrum Therapeutics has a market cap or net worth of $445.78M. The enterprise value is $285.14M.
Market Cap$445.78M
Enterprise Value$285.14M
Share Statistics
Fulcrum Therapeutics has 66,633,320 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding66,633,320
Owned by Insiders10.23%
Owned by Institutions58.94%
Financial Efficiency
Fulcrum Therapeutics’s return on equity (ROE) is -0.21 and return on invested capital (ROIC) is -23.84%.
Return on Equity (ROE)-0.21
Return on Assets (ROA)-0.20
Return on Invested Capital (ROIC)-23.84%
Return on Capital Employed (ROCE)-0.24
Revenue Per Employee0.00
Profits Per Employee-1.66M
Employee Count45
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Fulcrum Therapeutics is ―. Fulcrum Therapeutics’s PEG ratio is -0.02.
PE Ratio―
PS Ratio0.00
PB Ratio2.05
Price to Fair Value2.05
Price to FCF-11.87
Price to Operating Cash Flow-7.30
PEG Ratio-0.02
Income Statement
In the last 12 months, Fulcrum Therapeutics had revenue of 0.00 and earned -74.88M in profits. Earnings per share was -1.18.
Revenue0.00
Gross Profit-1.39M
Operating Income-84.77M
Pretax Income-74.88M
Net Income-74.88M
EBITDA-73.49M
Earnings Per Share (EPS)-1.18
Cash Flow
In the last 12 months, operating cash flow was -63.56M and capital expenditures -322.00K, giving a free cash flow of -63.88M billion.
Operating Cash Flow-63.56M
Free Cash Flow-63.88M
Free Cash Flow per Share-0.96
Dividends & Yields
Fulcrum Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.98
52-Week Price Change-6.45%
50-Day Moving Average7.40
200-Day Moving Average8.81
Relative Strength Index (RSI)31.33
Average Volume (3m)738.79K
Important Dates
Fulcrum Therapeutics upcoming earnings date is Aug 5, 2026, Before Open (Confirmed).
Last Earnings DateApr 27, 2026
Next Earnings DateAug 5, 2026
Ex-Dividend Date―
Financial Position
Fulcrum Therapeutics as a current ratio of 27.40, with Debt / Equity ratio of 1.76%
Current Ratio27.40
Quick Ratio27.40
Debt to Market Cap<0.01
Net Debt to EBITDA2.60
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Fulcrum Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Fulcrum Therapeutics EV to EBITDA ratio is -7.15, with an EV/FCF ratio of -8.70.
EV to Sales0.00
EV to EBITDA-7.15
EV to Free Cash Flow-8.70
EV to Operating Cash Flow-8.75
Balance Sheet
Fulcrum Therapeutics has $333.32M in cash and marketable securities with $5.87M in debt, giving a net cash position of $327.45M billion.
Cash & Marketable Securities$333.32M
Total Debt$5.87M
Net Cash$327.45M
Net Cash Per Share$4.91
Tangible Book Value Per Share$5.51
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Fulcrum Therapeutics is $18.44, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$18.44
Price Target Upside122.49% Upside
Analyst ConsensusModerate Buy
Analyst Count9
Revenue Growth Forecast-100.00%
EPS Growth Forecast-2365.81%